دورية أكاديمية
B Cell Profiling in Patients with Pemphigus Vulgaris.
| العنوان: | B Cell Profiling in Patients with Pemphigus Vulgaris. |
|---|---|
| المؤلفون: | Abrikosova VA; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Mokrushina YA; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation.; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, 119991 Russian Federation., Ovchinnikova LA; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Larina EN; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Terekhov SS; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Baranova MN; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Lomakin YA; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Balabashin DS; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Bobik TV; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Kaliberda EN; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Knorre VD; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation., Shpilevaya MV; State Research Center of Dermatovenereology and Cosmetology, Moscow, 107076 Russian Federation., Aliev TK; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation.; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, 119991 Russian Federation., Deryabin DG; State Research Center of Dermatovenereology and Cosmetology, Moscow, 107076 Russian Federation., Karamova AE; State Research Center of Dermatovenereology and Cosmetology, Moscow, 107076 Russian Federation., Kubanov AA; State Research Center of Dermatovenereology and Cosmetology, Moscow, 107076 Russian Federation., Kirpichnikov MP; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation.; Faculty of Biology, Lomonosov Moscow State University, Moscow, 119991 Russian Federation., Smirnov IV; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russian Federation.; Endocrinology Research Center, Moscow, 117292 Russian Federation. |
| المصدر: | Acta naturae [Acta Naturae] 2023 Jan-Mar; Vol. 15 (1), pp. 13-18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: National Research University Higher School of Economics Country of Publication: Russia (Federation) NLM ID: 101525823 Publication Model: Print Cited Medium: Print ISSN: 2075-8251 (Print) Linking ISSN: 20758251 NLM ISO Abbreviation: Acta Naturae Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : [Moscow] : National Research University Higher School of Economics Original Publication: Moscow : Park Media Ltd |
| مستخلص: | Pemphigus vulgaris is a severe, socially significant autoimmune disease associated with autoantibodies to the desmoglein 3 antigen. The disease affects all age groups, beginning at 18 years of age; the mortality rate of pemphigus can reach as high as 50%, depending on a patient's age and a number of other factors. There is no highly selective or personalized therapy for pemphigus vulgaris at the moment. One of the well-known therapeutic approaches to the disease is to use rituximab, an anti-CD20 antibody that can help achieve B cell depletion in peripheral blood. To solve the problem of nonspecific elimination of B cells in patients with pemphigus vulgaris, it is reasonable to use specific immunoligands, their choice being based on an assessment of the level of autoantibodies specific to each of the fragments of desmoglein. In this work, the proportion of autoreactive B cells in patients diagnosed with pemphigus vulgaris is found to be 0.09-0.16%; a positive correlation was revealed between the antibody level and the number of autoreactive B cells to various fragments of desmoglein. (Copyright ® 2023 National Research University Higher School of Economics.) |
| References: | Bull Exp Biol Med. 2021 Aug;171(4):475-479. (PMID: 34542752) Blood. 2011 Jul 14;118(2):348-57. (PMID: 21551230) Acta Naturae. 2020 Apr-Jun;12(2):63-69. (PMID: 32742728) J Drugs Dermatol. 2012 Oct;11(10):1200-6. (PMID: 23134985) Cell Rep. 2019 Jul 23;28(4):909-922.e6. (PMID: 31340153) Dermatol Ther. 2008 Jul;21 Suppl 1:S6-9. (PMID: 18727815) Acta Derm Venereol. 2010 Jul;90(4):401-5. (PMID: 20574606) Immunol Invest. 2009;38(6):498-509. (PMID: 19811408) PLoS One. 2011;6(6):e20991. (PMID: 21677771) Exp Dermatol. 2006 Aug;15(8):606-14. (PMID: 16842599) Acta Naturae. 2015 Apr-Jun;7(2):74-9. (PMID: 26085947) |
| فهرسة مساهمة: | Keywords: desmoglein 3; immunoligands; pemphigus vulgaris; targeted therapy |
| تواريخ الأحداث: | Date Created: 20230508 Latest Revision: 20231031 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10154782 |
| DOI: | 10.32607/actanaturae.11890 |
| PMID: | 37153513 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2075-8251 |
|---|---|
| DOI: | 10.32607/actanaturae.11890 |